APGE vs. VCEL, RXRX, KYMR, ADMA, CGON, SANA, NVAX, BEAM, IMCR, and TWST
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Kymera Therapeutics (KYMR), ADMA Biologics (ADMA), CG Oncology (CGON), Sana Biotechnology (SANA), Novavax (NVAX), Beam Therapeutics (BEAM), Immunocore (IMCR), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
Vericel (NASDAQ:VCEL) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
79.0% of Apogee Therapeutics shares are owned by institutional investors. 7.2% of Vericel shares are owned by company insiders. Comparatively, 36.1% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vericel currently has a consensus price target of $46.80, suggesting a potential downside of 9.18%. Apogee Therapeutics has a consensus price target of $73.00, suggesting a potential upside of 48.34%. Given Vericel's higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Vericel.
Vericel has a net margin of 0.22% compared to Vericel's net margin of 0.00%. Apogee Therapeutics' return on equity of 0.21% beat Vericel's return on equity.
In the previous week, Apogee Therapeutics had 9 more articles in the media than Vericel. MarketBeat recorded 15 mentions for Apogee Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 0.58 beat Apogee Therapeutics' score of 0.47 indicating that Apogee Therapeutics is being referred to more favorably in the news media.
Vericel has higher revenue and earnings than Apogee Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vericel received 320 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 62.22% of users gave Vericel an outperform vote.
Summary
Apogee Therapeutics beats Vericel on 8 of the 15 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
